Skip to main content

Table 3 Overview of demographic and clinical data as well as inter-group comparisons for the cohorts NMCLRRK2 and CON stratified by gender

From: Inflammatory profile in LRRK2-associated prodromal and clinical PD

 

Female

N = 152

Male

N = 96

Female

Male

 

NMCLRRK2

N = 63

CON

N = 89

NMCLRRK2

N = 52

CON

N = 44

p value

NMCLRRK2

CON

p value

NMCLRRK2

CON

Age

Years

51

23–84

57

18–83

54

27–82

58

28–83

0.087

0.110

UPDRS-III

0

0–13

0

0–9

0

0–15

0

0–8

0.021

0.542

MoCA

28

18–30

27

17–30

27

18–30

27

17–30

0.756

0.809

RBD Questionnaire

1

0–9

1

0–13

2

0–9

1

0–11

0.396

0.943

ESS

6

0–15

6

0–15

5

0–15

6

0–14

0.948

0.399

SCOPA-AUT

8

1–33

7

0–41

7

0–39

6

0–30

0.221

0.729

Regular anti-inflammatory medication

(% of individuals)

3.7

1.2

4.6

0.0

0.561

0.495

  1. Data are presented as median with range. p values reflect results from Mann–Whitney test. The intake of anti-inflammatory medication is given as % of individuals from the respective cohort; statistical analysis was done using chi-square test
  2. NMC LRRK2 non-manifesting LRRK2 mutation carriers, CON healthy control individuals, ESS Epworth Sleepiness Scale, HY Hoehn and Yahr Scale, LEDD levodopa-equivalent daily dosage, MoCA Montreal Cognitive Assessment, RBD REM sleep behavior disorder, UPDRS-III Unified Parkinson’s disease Rating Scale